This article was originally published in The Gray Sheet
Sells its GyneSys and HysteroSys infertility catheter product lines to Johnson & Johnson's Ethicon division for $975,000 plus deferred payments based on future product sales. Under terms of the deal, BEI will supply the products to Ethicon on a non-exclusive basis for up to a year. The move reflects BEI's concentration on core products in women's health and a focus on developing its Hydro ThermAblator system, which is currently in clinical trials, for treatment of excessive uterine bleeding, the company says
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.